Seeking Alpha

Investorideas.com's  Instablog

Investorideas.com
Send Message
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
View Investorideas.com's Instablogs on:
  • Technology Alert; Biometric Experts Comment On Launch Of Apple Pay Smart Wallet Payment Service

    Technology Alert; Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service

    New York, NY - Point Roberts, WA - September 12, 2014 - Investorideas.com (www.investorideas.com) a global news source covering leading sectors including biometrics and mobile tech , issues commentary from analysts and experts on the September 9th launch of Apple Pay, its new payment service . Alan Goode of Goode Intelligence, Janice Kephart, founder of the Secure Identity and Biometrics Association (SIBA) and CEO Gino Pereira of NXT-ID, Inc, (Nasdaq: NXTD) a company that is introducing its own biometric smart wallet that is separate from a smartphone.

    Alan Goode of Goode Intelligence, a well- known expert in biometrics noted, "Although not a revolutionary announcement from Apple, the introduction of Apple Pay using Touch ID for biometrically authenticated payments is a huge step towards the widespread adoption of mobile payments. Following on from the decision by PayPal and Alipay to both offer mobile payments to be authorised by fingerprint biometrics on the latest Samsung devices this is an indication that payments is a big driver for the adoption of consumer biometric authentication."

    Janice Kephart, founder of the Secure Identity and Biometrics Association (SIBA) talked about the future of biometrics and Apple's role "I think the easiest applications to predict having the biggest impact are the ones that are designed to be purely personal, voluntary, and would have little to no value to government, such as the Apple Watch which creates a highly unique fitness profile using biometric readings that actually informs people beyond what any fitness training apps do today. That is an innovation to move a biometric acceptance to a whole new level."

    She went on to say, "Much more tricky for Apple to launch is Apple Pay, which no matter how described, means that our phones are interfacing personal biometrics involuntary with an unknown web of payment systems, credit cards and retailers. It is that connectivity between personal biometrics and the outside world that is uncontrolled beyond - literally - our fingertips, that will continue to draw a dubious reaction from folks. Assuring people about who can access that biometric and payment information via their phones, and who cannot, is the learning curve Apple must overcome. Whether the public is ready or not remains to be seen. But no matter what, that acceptance will likely have less to do with the biometric features than with overall concerns about payment security and privacy."

    Frost & Sullivan reported today that "the biometric revenue from smart phones is expected to increase from $53.6 million in 2313 to $396.2 million in 2019, at a compound annual growth rate of 39.6 percent."

    "Due to existing hardware capabilities across devices, most of the growth is expected from facial and voice authentication technologies," said Frost & Sullivan ICT Global Programme Director Jean-Noel Georges. "While the uptake of biometric technologies will get a boost from the proliferation of new devices with fingerprint authentication capability, their acceptance will be tepid until the market develops more sophisticated and accurate authentication software."

    NXT-ID, Inc is launching a biometrically secure smart wallet called the Wocket that is separate from a consumer's smartphone that includes voice biometrics and a multiple security approach. The company announced yesterday that it began trading on the NASDAQ.

    CEO Gino Pereira of NXT-ID, Inc said," I think that the NFC solution offered by Apple will bring a wider acceptance of touchless payment technology. However the challenge is not be underestimated.

    Companies such as Google and SoftCard (formerly Isis) have been trying to implement NFC technology for several years and as recently as a year ago some pundits had written off the technology in favour of a cloud based solution. The payment industry is undergoing a revolution, just as the entertainment industry has over the last decade. At the heart of the matter, customers want to have the most convenient payment experience, which should also be as secure as possible. This experience can be delivered in many forms: a smartphone, a smart watch or our very own Wocket smart wallet! Security needs to address not only access through biometrics but also protection of the data through tokenization or encryption.

    Read this release in full at http://www.investorideas.com/CO/NXT/news/2014/09121.asp

    About Goode Intelligence: http://www.goodeintelligence.com

    Goode Intelligence providing independent insight that has a major influence on the market

    Goode Intelligence is an independent research and consultancy company that provides quality advice to global decision makers in business and technology.

    Goode Intelligence works in information security, mobile security, authentication and identity verification, biometrics, enterprise mobility and mobile commerce sectors.

    About Secure Identity and Biometrics Association (SIBA): http://www.sibassoc.org

    SIBA represents vendors, nonprofits, and research institutions dedicated to responsible use of innovations, including biometrics, that protect and secure identity.

    About NXT- ID Inc. - Mobile Security for a Mobile World

    NXT-ID, Inc.'s (NASDAQ:NXTD) innovative MobileBio™ solution mitigates consumer risks associated with mobile computing, m-commerce and smart OS-enabled devices. The company is focused on the growing m-commerce market, launching its innovative MobileBio™ suite of biometric solutions that secure consumers' mobile platforms led by the Wocket™; a next generation smart wallet designed to replace all the cards in your wallet, no smart phone required. The Wocket works anywhere credit cards are accepted and only works with your biometric stamp of approval. www.wocketwallet.com

    NXT-ID's wholly owned subsidiary, 3D-ID LLC, is engaged in biometric identification that has 22 licensed patents in the field of 3D facial recognition www.nxt-id.com www.3d-id.net

    About InvestorIdeas.com: www.investorideas.com

    InvestorIdeas.com is a global news source for investors following leading business sectors including biometric and mobile technology as well as other leading sectors.

    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

    Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

    Sign up for our free news alerts: http://www.investorideas.com/Resources/Newsletter.asp

    Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas.com has been engaged by NXTD for PR, media and news publication (five thousand per month plus 144 shares) Investor ideas is long shares. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

    BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

    Contact:

    800-665-0411

    www.Investorideas.com

    Sep 12 11:53 AM | Link | Comment!
  • CyberSecurity Stocks Directory Update; Cyber Security Market In The US Government Sector To Grow At A CAGR Of 7.41 Percent 2013-2018

    CyberSecurity Stocks Directory Update; Cyber Security Market in the US Government sector to grow at a CAGR of 7.41 percent 2013-2018

    New York, NY - Point Roberts, WA - August 21, 2014 (investorideas.com newswire) Investorideas.com staff: Investorideas.com, a global news source covering leading sectors releases the updated Cyber Security Stocks directory for August.

    "Cyber threats are internet-based attempts to attack information systems and hack critical information. These threats include hacking, malware, and phishing, and have the capability to capture all the critical information stored in information systems. Cyber security protects against cyber threats by identifying, monitoring, and resolving them while, at the same time, maintaining the confidentiality of information systems. It primarily involves measures taken to detect, monitor, report, and counter such threats. These solutions can be deployed as on-premises, cloud-based, or hybrid solutions. TechNavio's analysts forecast the Cyber Security Market in the US Government sector will grow at a CAGR of 7.41 percent during the period 2013-2018."

    Source:https://www.reportbuyer.com/product/2234311/cyber-security-market-in-the-us-government-sector-2014-2018.html

    Read this release in full at http://www.investorideas.com/news/2014/cybersecurity/08211.asp

    CyberSecurity Stocks August 2014

    Absolute Software Corporation (TSX:ABT.TO) is the industry standard in persistent endpoint security and management for computers, laptops, tablets and smartphones. The Company, a leader in device security and management tracking for 20 years, has over 30,000 commercial customers worldwide. Absolute's solutions - Computrace®, Absolute Manage®, Absolute Service, Absolute Secure Drive, and Absolute LoJack® - provide organizations with actionable intelligence to prove compliance, securely manage BYOD, and deliver comprehensive visibility and control over all of their devices and data. Absolute is positioned on two Gartner, Inc. Magic Quadrants - the Magic Quadrant for Client Management Tools and the Magic Quadrant for Mobile Device Management Software. Absolute is one of only four vendors to be recognized on both Magic Quadrants based on providing customers with the ability to secure and manage many different types of devices using a single solution. Absolute persistence technology is embedded in the firmware of computers, netbooks, tablets and smartphones by global leaders, including Acer, ASUS, Dell, Fujitsu, HP, Lenovo, Motion, Panasonic, Samsung, and Toshiba, and the Company has reselling partnerships with these OEMs and others, including Apple.

    AT&T Inc. (NYSE: T) AT&T Government Services (AGS), a business unit of AT&T Corp., delivers IT solutions spanning cyber security, networking, wireless, mission support and applications. Thousands of experienced AGS personnel, along with certified professionals throughout the AT&T family of companies, focus exclusively on supporting the federal government.

    AVG Technologies N.V. (NYSE:AVG) mission is to simplify, optimize and secure the Internet experience, providing peace of mind to a connected world. AVG's powerful yet easy-to‐use software and online services put users in control of their Internet experience. By choosing AVG's software and services, users become part of a trusted global community that benefits from inherent network effects, mutual protection and support. AVG has grown its user base to 172 million active users as of September 30, 2013 and offers a protection, performance and privacy products and services suite to consumers and small businesses including Internet security, performance optimization, mobile security, online backup, identity protection and family safety software.

    BlackBerry (Research in motion) (NasdaqGS:BBRY; TSX:BB.TO) a global leader in wireless innovation, revolutionized the mobile industry with the introduction of the BlackBerry® solution in 1999. Today, BlackBerry products and services are used by millions of customers around the world to stay connected to the people and content that matter most throughout their day. Founded in 1984 and based in Waterloo, Ontario, RIM operates offices in North America, Europe, Asia Pacific and Latin America. Integral security features and an ever-expanding administrative toolset have earned BlackBerry® products the trust of some of the most secure organizations in the world. These security features have also made the BlackBerry solution a world leader in mobile security certifications

    CA Technologies. (NasdaqGS:CA) provides IT management solutions that help customers manage and secure complex IT environments to support agile business services. Organizations leverage CA Technologies software and SaaS solutions to accelerate innovation, transform infrastructure and secure data and identities, from the data center to the cloud.

    Cecurity.com (Paris:MLCEC.PA) is a France-based software editing company that provides security solutions for data protection. The Company's main activities are software solutions and consulting services. Its products and services include Digital Vault Storage, a solution for data protection, tracking system, legal archiving and preservation of documents and electronic flows; electronic invoice system; software solution for public tender organization; legal archiving and digitization of documents. The Company's clients are banks, telecommunication operators, insurers, healthcare and other services, as well as ministries, courts, local authorities and professionals, among others.

    Check Point Software Technologies Ltd. (NasdaqGS:CHKP) a worldwide leader in securing the Internet, is the only vendor to deliver Total Security for networks, data and endpoints, unified under a single management framework. Check Point provides customers uncompromised protection against all types of threats, reduces security complexity and lowers total cost of ownership. Check Point first pioneered the industry with FireWall-1 and its patented stateful inspection technology. Today, Check Point continues to innovate with the development of the Software Blade architecture. The dynamic Software Blade architecture delivers secure, flexible and simple solutions that can be fully customized to meet the exact security needs of any organization or environment. Check Point customers include tens of thousands of businesses and organizations of all sizes including all Fortune 100 companies. Check Point's award-winning ZoneAlarm solutions protect millions of consumers from hackers, spyware and identity theft.

    Checkpoint Systems Inc. (NYSE:CKP) is a global leader in shrink management, merchandise visibility and apparel labeling solutions. Checkpoint enables retailers and their suppliers to reduce shrink, improve shelf availability and leverage real-time data to achieve operational excellence. Checkpoint solutions are built upon 40 years of RF technology expertise, diverse shrink management offerings, a broad portfolio of apparel labeling solutions, market-leading RFID applications, innovative high-theft solutions and its Web-based Check-Net® data management platform. As a result, Checkpoint customers enjoy increased sales and profits by improving supply-chain efficiencies, by facilitating on-demand label printing and by providing a secure open-merchandising environment enhancing the consumer's shopping experience.

    Cisco Systems Inc. (NASDAQGS: CSCO) is the worldwide leader in networking that transforms how people connect, communicate and collaborate. Industry Solutions include: CyberSecurity, Government Security, Public Safety and Security, Defense and Intelligence.

    CommVault Systems, Inc. (NasdaqGS:CVLT) A singular vision - a belief in a better way to address current and future data management needs - guides CommVault in the development of Singular Information Management® solutions for high-performance data protection, universal availability and simplified management of data on complex storage networks. CommVault's exclusive single-platform architecture gives companies unprecedented control over data growth, costs and risk. CommVault's Simpana® software suite of products was designed to work together seamlessly from the ground up, sharing a single code and common function set, to deliver superlative Data Protection, Archive, Replication, Search and Resource Management capabilities. More companies every day join those who have discovered the unparalleled efficiency, performance, reliability, and control only CommVault can offer.

    For full list and more directories: http://www.investorideas.com/membership/

    About InvestorIdeas.com:

    InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks and Latin American stocks.

    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

    Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

    Sign up for our free news alerts

    http://www.investorideas.com/Resources/Newsletter.asp

    Become an Investorideas.com Member and use our online stock directories to research stocks - including biometric, cyber and mobile payment stocks http://www.investorideas.com/membership/

    This news is published on the Investorideas.com Newswire and its syndicated partner network

    Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

    BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

    800-665-0411 - Source - www.Investorideas.com


    Aug 21 1:11 PM | Link | Comment!
  • Biotech News Alert: GenSpera's (OTCQB:GNSZ) CEO Shares Insight On Unique Properties And Targeting Of Lead Drug G-202, Based On The Thapsigargin Toxin

    Biotech News Alert: GenSpera's (OTCQB:GNSZ) CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin

    POINT ROBERTS, Wash. and NEW YORK - August 5, 2014 (Investorideas.com Biotech Newswire) Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB:GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells.

    He also shares insight into the key points that make them different from competitive drugs available on the market for certain cancers.

    Q: Investorideas.com

    Craig for readers unfamiliar with your company, can you explain the basis for your lead drug G-202 and how it works?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    There are really two important characteristics that distinguish G-202 from other chemotherapeutic agents. First, the active ingredient in G-202 is much more potent than other anti-cancer drugs and kills in a way that does not allow tumor cells to escape being killed. Second, G-202 is designed as a pro-drug that is expected to release the active ingredient only at the tumor itself, thereby maximizing anti-tumor effect and minimizing side effects.

    Q: Investorideas.com

    And in particular can you explain how the targeting kills the tumor only and give us insight into the safety profile?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    G-202 is designed so that it may be activated by the enzyme PSMA that is found at high levels in the blood vessels of almost all types of solid tumors, on the surface of prostate cancer cells and at very few other places in the body. G-202 circulates safely in the bloodstream until it comes in contact with PSMA which releases the active ingredient, 12ADT, which then falls into the tumor and does not come back into the bloodstream to cause toxicity elsewhere in the body. G-202 is administered to patients as an IV infusion over about one hour on three consecutive days - this dosing regimen is repeated at 28-day intervals. In keeping with the way G-202 is designed, patients experience very minor and easily managed side effects of nausea on days of drug administration, fatigue for a few days and a minor temporary rash. Importantly, G-202 has no effect on the bone marrow so there is no immunosuppression or anemia. This lack of significant side effects implies that we should be able to combine G-202 with other anti-cancer agents to maximize killing of the cancerous tumors in patients.

    Q: Investorideas.com

    The company just recently released G-202 hepatocellular carcinoma ("HCC", which is liver cancer) clinical trial data at two prestigious industry conferences. Can you summarize the results released and also how has the data been embraced by your industry peers?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    We are testing G-202 in hepatocellular carcinoma patients who have had tumors regrow after being treated with sorafenib, which is the only approved drug for this patient population. Those patients who fail sorafenib and subsequently enter clinical trials for other experimental drugs usually have documented tumor regrowth at only two months. In our G-202 study we found that 80% of patients exhibited disease stabilization (no tumor regrowth) at 2 months. We also demonstrated that a significant proportion of patients, approximately 30%, have tumors stop growing for at least six months with one patient still receiving drug two years after coming into the trial. We then used a sophisticated imaging technique that visualizes blood flow through the tumor in a patient before starting our drug and again after two cycles of treatment to show that G-202 dramatically diminishes blood flow to the tumor, presumably by destroying the tumor blood vessels. The consensus among our industry peers is that G-202 is an active drug that does exactly what it is designed to do and at doses that are very well-tolerated by the patients.

    Q: Investorideas.com

    Can you talk about the multiple cancers that G-202 can potentially treat and the kind of market opportunity each represents?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    We expect G-202 to be useful in a wide range of malignant tumor types, which covers a multi-billion dollar industry opportunity for GenSpera. There are approximately 240,000 new cases of prostate cancer diagnosed in the US each year. The market for prostate cancer drugs is expected to reach $6.7 billion by 2020. Hepatocellular carcinoma is the third largest cancer killer worldwide with an expected market size of $1.5 billion by 2019. Glioblastoma is a smaller market but sales of the approved drug Avastin in those patients is expected to reach $460 million by 2017. However we view glioblastoma as a proof of concept for treating brain tumors; if successful, we expect that G-202 could be used to treat lung and breast cancers that metastasize to the brain, which is a 10-fold larger market than glioblastoma alone.

    Q: Investorideas.com

    How would you describe the G-202 proof of concept to-date in terms that an average reader could understand, outside of the scientific community?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    G-202 is designed to be activated only within the blood vessels of tumors and to kill those blood vessels directly, thus starving the tumors to death. We used a very sophisticated imaging technique to demonstrate that G-202 treatment nearly obliterated tumor blood flow in a liver cancer patient after only two cycles of treatment. These results bode well for our prostate cancer and glioblastoma (brain cancer) clinical trials, which use exactly the same dosing regimen.

    Q: Investorideas.com

    Craig with your recent data on hepatocellular carcinoma (HCC or liver cancer) can you tell our readers how that compares with the current drug in the market?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    Sorafenib is the only approved drug for HCC and is used as the first line chemotherapy option. G-202 has only been tested in patients who have had tumor progression while on sorafenib and who are obviously patients of a later cancer stage. The fact that we are seeing positive signs of drug activity in this later stage patient population implies that we should see good activity when we test the drug in earlier stage patients. Certainly the G-202 side effect profile is much better than sorafenib, which causes nausea, neutropenia and hand-foot syndrome (blistering and peeling of palms of hands and soles of feet) in a significant proportion of patients.

    Q: Investorideas.com

    In closing can you summarize the next steps and estimated time-line forbringing G-202 to market?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    We continue to evaluate G-202 in the ongoing HCC, glioblastoma and prostate cancer trials, which are all considered early-stage single-arm studies. Our next trial with G-202 will likely be a small randomized Phase IIB study in combination with sorafenib or in combination with trans-arterial chemoembolization, both of which would be in much earlier stage cancer patients than those we have treated to date. Either study should be complete within two years at which time we could begin a Phase III registration study so we are likely to be six years away from commercialization in HCC. However, if our data is really positive in the glioblastoma trial, we likely could be approved a year or two earlier in that indication. In both cases as we report strong progress to the market, a strategic partnership with a major industry player is a possibility prior to receiving FDA approval.

    Watch the Corporate Video: http://youtu.be/jULjEul-mBk

    Read this release in full at http://www.investorideas.com/CO/GNSZ/news/2014/08051.asp

    Dr. Craig A. Dionne, PhD, President and CEO

    Craig A. Dionne, PhD, is one of Genspera's founders and has served on the board since November 2003. He has over 25 years of experience in the pharmaceutical industry, including direct experience in identifying promising oncology treatments and bringing them through the clinic. He served for several years as VP Discovery Research at Cephalon, Inc. (now Teva Pharmaceuticals), a biopharmaceutical company, where he was responsible for its oncology and neurobiology drug discovery and development programs. Dr. Dionne also served as Executive Vice President at the Prostate Cancer Research Foundation. In addition to extensive executive experience, Dr. Dionne's productive scientific career has led to six issued patents and co-authorship of many scientific papers. Dr. Dionne received his PhD from the University of Texas at Austin in 1984.

    About GenSpera (OTCQB:GNSZ):

    GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a pro-drug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

    G-202 Phase II clinical trials are underway in hepatocellular carcinoma, glioblastoma and prostate cancer patients.

    For more information, please visit the company's website: http://www.genspera.com or follow on Twitter @GenSperaNews.

    InvestorIdeas.com is a global news source and research resource covering leading sectors including social media, tech, biotech, defense, water, mining and energy.

    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

    Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

    Sign up for free news alerts at Investorideas.com:

    http://www.investorideas.com/Resources/Newsletter.asp

    Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors: http://www.investorideas.com/membership

    Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (OTCQB:GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)

    BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

    Contact Investorideas.com: 800-665-0411

    Aug 05 1:56 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.